AI Engines For more Details: Perplexity Kagi Labs You
Protozoal Infections: Tizoxanide is effective against a variety of protozoal infections, including:
Mechanism of Action: Tizoxanide works by interfering with the pyruvate-ferredoxin oxidoreductase enzyme-dependent electron transfer reaction, leading to disruption of energy metabolism and inhibition of parasite growth and replication.
Administration: Tizoxanide is typically administered orally in tablet or suspension form. The dosage and duration of treatment depend on the type and severity of the infection being treated. It is usually taken with food to enhance absorption and minimize gastrointestinal side effects.
Adverse Effects: Common side effects of tizoxanide are generally mild and may include nausea, vomiting, diarrhea, abdominal pain, headache, and dizziness. These side effects are usually transient and resolve once treatment is completed.
Pregnancy and Lactation: The safety of tizoxanide during pregnancy and lactation has not been well established. Pregnant or breastfeeding women should consult their healthcare provider before using tizoxanide to weigh the potential benefits against the risks.
Drug Interactions: Tizoxanide may interact with certain medications, although significant drug interactions are less common compared to nitazoxanide. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting tizoxanide treatment.
Resistance: As with other antiparasitic medications, the inappropriate use of tizoxanide can contribute to the development of drug-resistant parasites. It is essential to use tizoxanide judiciously and according to healthcare provider's instructions to minimize the emergence of resistance.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium animalis | Reduces |
| species | Bifidobacterium bifidum | Reduces |
| species | Bifidobacterium breve | Reduces |
| species | Bifidobacterium catenulatum | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Bifidobacterium pseudocatenulatum | Reduces |
| species | Bifidobacterium pseudolongum | Reduces |
| species | Propionibacterium freudenreichii | Reduces |
| species | Veillonella atypica | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 1 | 1 | |
| Acne | 0.5 | 0.5 | 0 |
| ADHD | 3.5 | 0.4 | 7.75 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | 0 |
| Allergic Rhinitis (Hay Fever) | 1.5 | 1.8 | -0.2 |
| Allergies | 5.2 | 3.9 | 0.33 |
| Allergy to milk products | 1.7 | 1.1 | 0.55 |
| Alopecia (Hair Loss) | 0.5 | 0.8 | -0.6 |
| Alzheimer's disease | 4.9 | 3.7 | 0.32 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 1.3 | 0.08 |
| Ankylosing spondylitis | 2 | 2.9 | -0.45 |
| Anorexia Nervosa | 1.2 | 2 | -0.67 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 4.4 | 2.2 | 1 |
| Atherosclerosis | 3.1 | 1.3 | 1.38 |
| Atrial fibrillation | 3.1 | 1.6 | 0.94 |
| Autism | 5.7 | 5.8 | -0.02 |
| Autoimmune Disease | 1 | 0.7 | 0.43 |
| Barrett esophagus cancer | 1 | 0.3 | 2.33 |
| benign prostatic hyperplasia | 0.5 | -0.5 | |
| Biofilm | 1 | 1 | |
| Bipolar Disorder | 1.5 | 2.3 | -0.53 |
| Brain Trauma | 0.6 | 2.6 | -3.33 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 1.5 | 1.2 | 0.25 |
| Carcinoma | 3.1 | 1.8 | 0.72 |
| Celiac Disease | 3.1 | 3.5 | -0.13 |
| Cerebral Palsy | 2 | 1.3 | 0.54 |
| Chronic Fatigue Syndrome | 3.8 | 2.9 | 0.31 |
| Chronic Kidney Disease | 1.6 | 0.4 | 3 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 2.4 | -0.6 |
| Chronic Urticaria (Hives) | 0.7 | 1 | -0.43 |
| Coagulation / Micro clot triggering bacteria | 1 | -1 | |
| Cognitive Function | 2.2 | 0.7 | 2.14 |
| Colorectal Cancer | 4.8 | 2.7 | 0.78 |
| Constipation | 1.8 | 0.9 | 1 |
| Coronary artery disease | 1 | 2.4 | -1.4 |
| COVID-19 | 6.1 | 6.6 | -0.08 |
| Crohn's Disease | 5.2 | 3.3 | 0.58 |
| Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
| cystic fibrosis | 0.2 | 1.3 | -5.5 |
| deep vein thrombosis | 1.1 | 1.6 | -0.45 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 5.8 | 5.9 | -0.02 |
| Dermatomyositis | 0.5 | -0.5 | |
| Eczema | 1.3 | 2.2 | -0.69 |
| Endometriosis | 2.4 | 1.3 | 0.85 |
| Eosinophilic Esophagitis | 1 | 0.5 | 1 |
| Epilepsy | 3.4 | 1.3 | 1.62 |
| erectile dysfunction | 1 | 0.7 | 0.43 |
| Fibromyalgia | 0.7 | 1.5 | -1.14 |
| Functional constipation / chronic idiopathic constipation | 5 | 2.9 | 0.72 |
| gallstone disease (gsd) | 1.7 | 1.5 | 0.13 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.6 | 0.9 | 1.89 |
| Generalized anxiety disorder | 1.5 | 2 | -0.33 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.5 | 0.7 | -0.4 |
| Gout | 1.9 | 0.2 | 8.5 |
| Graves' disease | 2.6 | 2.1 | 0.24 |
| Gulf War Syndrome | 0.2 | 1.5 | -6.5 |
| Halitosis | 2.9 | 2.9 | |
| Hashimoto's thyroiditis | 3.3 | 1.3 | 1.54 |
| Heart Failure | 1.9 | 2 | -0.05 |
| hemorrhagic stroke | 0.5 | 0.5 | |
| Hidradenitis Suppurativa | 1.8 | 0.5 | 2.6 |
| High Histamine/low DAO | 0.7 | 1.4 | -1 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | |
| hyperglycemia | 0.7 | 0.8 | -0.14 |
| Hyperlipidemia (High Blood Fats) | 1 | 1 | |
| hypersomnia | 0.5 | 0.5 | |
| hypertension (High Blood Pressure | 2.9 | 4.4 | -0.52 |
| Hypothyroidism | 1 | 0.7 | 0.43 |
| Hypoxia | 1.5 | 1 | 0.5 |
| IgA nephropathy (IgAN) | 2.1 | 4.1 | -0.95 |
| Inflammatory Bowel Disease | 5.8 | 6.4 | -0.1 |
| Insomnia | 2.3 | 2 | 0.15 |
| Intelligence | 1.4 | 0.9 | 0.56 |
| Intracranial aneurysms | 1.8 | 0.8 | 1.25 |
| Irritable Bowel Syndrome | 5.5 | 4.3 | 0.28 |
| ischemic stroke | 3 | 1.1 | 1.73 |
| Liver Cirrhosis | 4.8 | 3.5 | 0.37 |
| Long COVID | 4.2 | 6.4 | -0.52 |
| Low bone mineral density | 0.3 | 1.1 | -2.67 |
| Lung Cancer | 0.3 | 1 | -2.33 |
| Mast Cell Issues / mastitis | 0.1 | 1.9 | -18 |
| ME/CFS with IBS | 0.2 | 0.8 | -3 |
| ME/CFS without IBS | 0.2 | 0.8 | -3 |
| membranous nephropathy | 0.5 | 0.5 | |
| Menopause | 2.1 | 0.3 | 6 |
| Metabolic Syndrome | 4.6 | 6.2 | -0.35 |
| Mood Disorders | 6.6 | 6.1 | 0.08 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
| Multiple Sclerosis | 3.9 | 3 | 0.3 |
| Multiple system atrophy (MSA) | 1.1 | -1.1 | |
| myasthenia gravis | 0.2 | -0.2 | |
| neuropathic pain | 0.3 | -0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.3 | 3.6 | -0.09 |
| NonCeliac Gluten Sensitivity | 1 | 0.8 | 0.25 |
| Obesity | 5.3 | 5.6 | -0.06 |
| obsessive-compulsive disorder | 3.1 | 2.3 | 0.35 |
| Osteoarthritis | 1.5 | 1.4 | 0.07 |
| Osteoporosis | 1.9 | 0.6 | 2.17 |
| pancreatic cancer | 0.9 | 0.9 | |
| Parkinson's Disease | 3.5 | 5.2 | -0.49 |
| Polycystic ovary syndrome | 4.1 | 2.7 | 0.52 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.5 | -1.5 |
| Premenstrual dysphoric disorder | 0.5 | 0.5 | |
| primary biliary cholangitis | 1.8 | 0.9 | 1 |
| Primary sclerosing cholangitis | 2.4 | 0.7 | 2.43 |
| Psoriasis | 3.5 | 0.8 | 3.38 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 3.6 | 0.11 |
| Rosacea | 1.5 | 0.2 | 6.5 |
| Schizophrenia | 5.8 | 2.8 | 1.07 |
| scoliosis | 0.8 | 1 | -0.25 |
| Sjögren syndrome | 1.8 | 1.5 | 0.2 |
| Sleep Apnea | 2 | 1.1 | 0.82 |
| Slow gastric motility / Gastroparesis | 2.3 | 1 | 1.3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.5 | 3.4 |
| Stress / posttraumatic stress disorder | 1.5 | 0.8 | 0.88 |
| Systemic Lupus Erythematosus | 3.9 | 1.9 | 1.05 |
| Tic Disorder | 1.7 | 1.4 | 0.21 |
| Tourette syndrome | 0.5 | -0.5 | |
| Type 1 Diabetes | 3.9 | 3.8 | 0.03 |
| Type 2 Diabetes | 5.2 | 6 | -0.15 |
| Ulcerative colitis | 4 | 5.1 | -0.27 |
| Unhealthy Ageing | 2.4 | 1.4 | 0.71 |
| Vitiligo | 1.8 | 0.7 | 1.57 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
